 | | Vol. 8.32 – 27 August, 2020 |
| |
|
|
| Investigators performed a controlled, non-randomized, Phase I clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.
[Signal Transduction and Targeted Therapy] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Within CD34+ hematopoietic stem and progenitor cells the authors identified CD34+CD38+ progenitor cells as a highly apoptosis-resistant population, while CD34+CD38− hematopoietic stem/multipotent progenitor cells as a population very sensitive to radiation-induced apoptosis.
[Scientific Reports] |
|
|
|
| Researchers classified dynamic changes in the maternal lipidome during pregnancy and identified lipids associated with Fenton birth weight z-score and the umbilical cord blood lipidome.
[Scientific Reports] |
|
|
|
| To explore the tenogenic responsiveness of human bone marrow-MSCs and human Wharton’s jelly-MSCs to human Growth Differentiation Factor 5, scientists supplemented each at doses of 1, 10, and 100 ng/mL of hGDF-5 and determined proliferation, morphology and time-dependent expression of tenogenic markers.
[International Journal of Molecular Sciences] |
|
|
|
| 54 patients were randomized to receive human umbilical cord-MSCs or bone-marrow-derived mononuclear cells in combination with coronary artery bypass-grafting (CABG) surgery. The control patients received no cells/vehicles but CABG intervention.
[International Journal of Stem Cells] |
|
|
|
| Lineage-negative umbilical cord blood-derived cells -enriched for hematopoietic stem and progenitor cells- were cultured in presence of different combinations of hematopoietic cytokines, neurotrophins, epidermal growth factor, fibroblast growth factor, and neurogenic culture media, in a three-phase culture system.
[Blood Cells Molecules and Diseases] |
|
|
|
| CD34+ and CD133+ were longitudinally detected by flow cytometry in the maternal plasma of 29 healthy controls and nine multiple sclerosis patients and in the cord blood of their newborns.
[Neurological Sciences] |
|  |
|
|
|
| The ongoing studies on coronavirus are using mesenchymal stem cells derived from bone marrow or the umbilical cord to demonstrate their feasibility, safety, and tolerability.
[Stem Cell Reviews and Reports] |
|
|
|
|
| NantKwest, Inc. announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic. The two product candidates currently in development under the agreement are a mesenchymal stem celltherapeutic from NantKwest, whose goal is to reduce the time a critically ill patient spends on a ventilator; and a COVID-19 vaccine product from ImmunityBio, which is anticipated to soon enter into a Phase I clinical trial.
[NantKwest, Inc.] |
|
|
|
|
| September 10-17, 2020
Virtual |
|
|
|
|
|
| | Pennsylvania State University – Philadelphia, Pennsylvania, United States |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York City, New York, United States |
|
|
|
| | Myeloid Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| | University of Massachusetts – Amherst, Massachusetts, United States |
|
|
|
| | Huntington Medical Research Institutes – Pasadena, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
